Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany.
Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.
PLoS One. 2020 Apr 2;15(4):e0231027. doi: 10.1371/journal.pone.0231027. eCollection 2020.
qPET is a quantitative method used to assess FDG-PET response in lymphoma. qPET was developed using 898 scans from children with Hodgkin Lymphoma (HL) in the EuroNet-PHL-C1 (C1) trial. The aim of this study was to determine if qPET could be applied as an alternative response method in adults in the RAPID trial.
PET-CT scans performed after 3 cycles of ABVD in RAPID were re-evaluated by an independent reader, blinded to PET results and outcome in RAPID. All initially involved regions were assessed visually and by qPET. The distribution of qPET measurements was compared for RAPID and C1 patients. Previously published qPET thresholds corresponding to visual DS (vDS) of 1-5 in C1 were used to derive quantitative DS (qDS) for RAPID patients.
PET-CT scans were available for 450 patients from RAPID. vDS were 1 (171 scans), 2 (153 scans), 3 (72 scans), 4 (31 scans) and 5 (23 scans) respectively. The distribution of qPET values was similar to C1 patients, with a unimodal 'normal' distribution and a long tail to the right, suggestive of favorable response in the majority and less favorable response in the minority with outlying values. qPET thresholds from C1 applied in RAPID patients gave 86% concordance for vDS and qDS. There was 97% concordance for complete metabolic response (CMR; DS 1-3) vs. no-CMR using the Lugano classification.
qPET which was developed in pediatric patients receiving more intensive OEPA chemotherapy, was a suitable quantitative method for assessing response in adult patients treated with ABVD in a response-adapted setting in the RAPID trial.
qPET 是一种用于评估淋巴瘤 FDG-PET 反应的定量方法。qPET 是使用 EuroNet-PHL-C1（C1）试验中儿童霍奇金淋巴瘤（HL）的 898 个扫描结果开发的。本研究的目的是确定 qPET 是否可作为 RAPID 试验中成人的替代反应方法。
在 RAPID 中进行 3 个 ABVD 周期后进行的 PET-CT 扫描由一位独立的读者重新评估，该读者对 PET 结果和 RAPID 中的结果均不知情。所有最初涉及的区域均通过 qPET 进行视觉评估。比较了 RAPID 和 C1 患者的 qPET 测量分布。先前发表的 qPET 阈值对应于 C1 中的视觉 DS（vDS）1-5，用于为 RAPID 患者得出定量 DS（qDS）。
RAPID 共有 450 名患者可获得 PET-CT 扫描。vDS 分别为 1（171 个扫描），2（153 个扫描），3（72 个扫描），4（31 个扫描）和 5（23 个扫描）。qPET 值的分布与 C1 患者相似，具有单峰“正常”分布和右侧长尾，提示大多数患者的反应良好，少数患者的反应较差，且存在异常值。在 RAPID 患者中应用 C1 中的 qPET 阈值，vDS 和 qDS 的一致性为 86%。根据 Lugano 分类，完全代谢缓解（DS 1-3）与无代谢缓解（no-CMR）的一致性为 97%。
qPET 是在接受更强化的 OEPA 化疗的儿科患者中开发的，是一种适合评估 RAPID 试验中接受 ABVD 治疗的适应反应的成年患者反应的定量方法。
